ArticleCancer medicine2026
Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundSome patients with clinically node-positive (cN1) breast cancer (BC) can achieve axillary pathological complete response (apCR) in axillary lymph nodes (ALNs) after neoadjuvant therapy (NAT). This study investigated predictors of post-NAT pathological node-negative (ypN0) status in cN1 breast cancer patients to identify candidates for omitting sentinel lymph node biopsy (SLNB).
methodsThis study included patients diagnosed with stage cT1-4 N1 breast cancer who received NAT followed by breast surgery and axillary lymph node dissection (ALND) at the Breast Surgery Department of the Affiliated Hospital of Southwest Medical University between January 2020 and April 2025. Univariate and multivariate logistic regression analyses were conducted to identify factors predictive of ypN0 status across different molecular subtypes.
resultsThis study enrolled 357 patients: 147 achieved ycN0 after NAT, while 210 remained ycN1. Multivariate analysis revealed: in ycN0 patients, only breast pathological complete response(bpCR) predicted ypN0 (OR: 0.151, 95% CI: 0.055-0.419); in ycN1 patients, both bpCR (OR: 0.038, 95% CI: 0.015-0.098) and MRI radiological complete response of lymph nodes (MRI-rCR(LN))(OR: 0.36, 95% CI: 0.156-0.832) were significant predictors. Univariate analysis identified ten ypN0-associated factors including bpCR. Luminal B HER2+ subtypes showed significantly higher ypN0 rates versus other subtypes.
conclusionsSpecific predictors (notably bpCR and MRI-rCR(LN)) are strongly associated with ypN0 in cN1 BC post-NAT, with Luminal B HER2+ patients demonstrating superior response rates. These findings support selective SLNB omission in cN1 patients achieving these key response markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.